Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
AbbVie, adalimumab, adaptive, ahead, aimed, angina, apotex, ASCO, ASN, ATRA, Avastin, Balachandran, balugrastim, BCA, belonging, BESP, bioequivalence, biopharmaceutical, BP, brodalumab, Carolina, CaSR, Celltech, cheaper, cholesterol, clarifying, cognitive, College, commentary, confronted, counterfeit, counterfeiting, curbing, cyber, Cynthia, DC, deCODE, destruction, devote, Durgin, eckert, engineering, exacting, extracellular, familial, fatal, flexibility, footprint, foster, frame, Freeman, GCTB, German, glycine, great, greatly, guilty, Hood, HUMIRA, hyperlipidemia, hypersensitivity, incentivized, infarction, infliximab, Inspector, intrusion, IQWiG, irreversible, ixekizumab, KAI, Kenneth, landscape, Latin, leader, Leroy, linked, LP, Madhavan, Madhu, minimal, minimize, misbranding, misdemeanor, MN, multitude, Mustafa, Neupeg, Nevzat, NHL, NOL, outlicensing, page, passage, Patton, pedigree, Pharma, pioneer, plea, Poland, preexisting, prepaid, privacy, prolonged, prominence, Purnell, rare, redemption, Reed, regularly, relapsed, REMICADE, repeal, replenished, requisite, residential, rituximab, romosozumab, Rosenblum, ROW, SCAN, schizophrenia, spur, statin, stolen, stored, strength, sum, supplementary, surface, surrogate, Taxpayer, theft, tibia, today, TPE, transit, transition, transitioning, trastuzumab, trebananib, Turkey, Tyler, ulcerative, unanticipated, unavailable, unbilled, undiscounted, unlawfully, unsafe, unstable, vertebral, vitro, withholding, worsening, Xeljanz
Removed:
accompanied, Advisor, ALJ, Alliance, alternatively, amounting, amplify, Anna, anticipation, arm, asLarson, assert, asserting, attracting, awarded, AWP, backed, background, Baxter, bear, Behring, Beier, bill, biology, BioScience, Bonanni, broadly, captionedIn, captionedLarson, carboplatin, cellular, Chevron, collective, column, comment, concentrate, Constance, constitute, consumer, contractility, convict, counted, Cytyc, Daiichi, Dear, deceptive, dermatology, detailed, Dey, diphosphate, discontinue, dispensing, dissemination, Electric, elevating, enforceable, England, entitledThe, EPO, estimable, exemption, exercising, Fabrizio, falsely, forfeiture, FOSAMAX, Fujisawa, furnish, Gensia, geographical, GRANULOKINE, Grumman, guideline, half, Hartson, hazard, head, hematocrit, hereto, Hoechst, Hogan, holding, House, hypocalcemia, Ilypsa, inhibit, initiating, innovating, inRosenblum, instruction, interval, ischemia, ITC, Journal, Justice, locally, Marion, MCI, MDL, Mellon, modality, Mountain, neck, Northern, Northrop, notified, OCI, ofDurgin, ofRosenblum, ONJ, opposing, opposition, paclitaxel, pancreatic, pediatric, peg, penetration, Pharmacia, Pharmacopoeia, Philadelphia, predominately, proceed, proceeding, quickly, registry, rehearing, reimburse, resolving, restructure, retaining, rheumatology, Richo, Roussel, Sandoz, Sankyo, satisfied, secreted, secretion, selectively, SF, spent, stipulated, studied, suited, suspended, tentative, terminating, territory, Tevagrastim, theIn, Thompson, timetable, tissue, titledBirch, track, training, trustee, Turner, undetermined, unlawful, unusual, Upjohn, vacated, violating, vision, weighting, Welfare, withdrew, yearly, ZLB
Filing tables
Filing exhibits
- 10-K Annual report
- 3.5 Charter Certificate
- 10.4 Amended Performance Award Program
- 10.6 Amended and Restated Director Program
- 10.8 Form of Restricted Stock Unit Agreement for Director Program
- 10.17 First Amendment to the Executive Incentive Plan
- 10.51 Amendment 1 to License Agreement
- 10.52 Amendment 2 to License Agreement
- 10.54 Collaboration and License Agreement and Amendment 1
- 10.58 Amendment 1 to Collaboration Agreement
- 10.61 Amendment 2 to Expansion Agreement
- 10.63 Amendment 1 to Sourcing and Supply Agreement
- 21 Subsidiaries of the Company
- 31 Rule 13A-14(A) Certifications
- 32 Section 1350 Certifications
Related press release
AMGN similar filings
Filing view
External links
Exhibit 10.17
FIRST AMENDMENT TO THE
AMGEN INC. EXECUTIVE INCENTIVE PLAN
(AMENDED AND RESTATED EFFECTIVE JANUARY 1, 2009)
The Amgen Inc. Executive Incentive Plan (As Amended and Restated, Effective January 1, 2009) (the “Plan”) is hereby amended, effective December 13, 2012, as follows:
The following paragraph shall be inserted immediately following the second paragraph in Section VI:
If a Participant engaged in misconduct that caused serious financial or reputational damage to the Company during any performance period, including a previous performance period, the Compensation Committee may determine that an award has not been earned or may consider such conduct when determining the amount of any award. This provision is in no way intended to limit any other action that the Company could take against a Participant (including other disciplinary actions (up to termination), ordinary course performance considerations, disclosure of wrongdoing to the government and pursuit of any other legal claims against such Participant).
To record this First Amendment to the Plan as set forth herein, effective December 13, 2012, Amgen Inc. has caused its authorized officer to execute this document this 7th day of January, 2013.
AMGEN INC.
By: /s/ Brian McNamee
Brian McNamee
Senior Vice President
Human Resources
1